Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Plant Extract Reduced Signs of IPF in Mice

An extract of the plant Lemna minor L., also called duckweed, suppresses the signs and symptoms of idiopathic pulmonary fibrosis (IPF) in disease-induced mice, a study suggests. More research to evaluate dosing and oral availability is recommended, study  authors noted. “Pulmonary Protein Oxidation and Oxidative Stress…

Inhaled IPF Therapy LTI-03 Well-Tolerated in Healthy Volunteers

Lung Therapeutics’ LTI-03, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF), was safe and well-tolerated in healthy volunteers, with no reports of serious adverse events (side effects) or discontinuations, according to a Phase 1a trial. “We are pleased that LTI-03 has passed this important safety milestone as…

Haduvio Succeeds at Easing Chronic Cough of IPF in Phase 2 CANAL Trial

The investigational oral therapy Haduvio (nalbuphine extended-release tablets) significantly reduced chronic cough in people with idiopathic pulmonary fibrosis (IPF), according to interim results from the proof-of-concept Phase 2 CANAL trial. Findings in 26 patients showed a mean 51.7% placebo-adjusted decline in daytime cough frequency with the treatment, meeting the…

FDA Gives Breakthrough Therapy Status to Oral BI-1015550 for IPF

The U.S. Food and Drug Administration (FDA) has given breakthrough status to Boehringer Ingelheim’s BI-1015550, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), based partly on the findings of a clinical trial in IPF patients. A breakthrough therapy designation works to speed the development and review of…

Analysis of Lung Tissue Reveals Important Genetic Drivers of IPF

An analysis of gene activity profiles in lung tissue has identified important drivers of idiopathic pulmonary fibrosis (IPF). The genes discovered in this integrative analysis may predict disease outcomes and be used as potential therapeutic targets for new anti-fibrotic treatments, according to researchers. The study, “Integrative…